5-Year Safety Data From Upadacitinib Trials Reported 5-Year Safety Data From Upadacitinib Trials Reported

Upadacitinib trials in atopic dermatitis have included diverse patient groups with varying risk factors, according to Dr Christopher Bunick.MDedge News

Source: Medscape Dermatology Headlines - January 3, 2024 Category: Dermatology Tags: Dermatology Source Type: news